The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days

Journal of Cancer Research and Clinical Oncology

Volumn 119, Issue 9, 1993, Pages 555-559

  Aapro, M ^a   Piguet, D ^a   Giger, K ^a   Bauer, J ^a   Haefliger, JM ^a   Bremer, K ^b   Cals, L ^c   Cattan, A ^d   Clavel, M ^e   Czygan, P ^f   Dearnaley, D ^g   Diehl, V ^h   Harjung, M ⁱ   Harper, P ^j   Illiger, H ^k   Kaye, S ^l   Keizer, H J ^m   Kerbrat, P ⁿ   Konig H J ^o   Moncuquet, P ^p   Namer, M ^q   Nobel, A ^r   Nortier, J W R ^s   Oberling, F ^t   Plagne, R ^u   Reichle, A ^v   Riviere A ^w   Soukop, M ^x   Veenhof, C H N ^y   Zylberait, D ^z   Hunter, B ^aa   more..

^a Krankenanstalten Augusta ^*

^b Augusta Kranken Anstalt   (Germany)

^c Centre de Gerontologie Georges CLEMENCEAU   (France)

^d INSTITUT JEAN GODINOT   (France)

^e CENTRE LÉON BÉRARD   (France)

^f Lukaskrankenhaus GmbH   (Germany)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ KLINIKUM DARMSTADT   (Germany)

^j GUY S HOSPITAL   (United Kingdom)

^k KLINIKUM OLDENBURG   (Germany)

^l WESTERN INFIRMARY   (United Kingdom)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ CENTRE EUGÈNE MARQUIS   (France)

^o UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^p UNIVERSITY HOSPITAL OF BESANÇON   (France)

^q CENTRE ANTOINE LACASSAGNE   (France)

^r St Inrichting Van Diakonessen ^*  (France)

^s DEPARTMENT OF SURGERY   (Netherlands)

^t HÔPITAL DE HAUTEPIERRE   (France)

^u CENTRE JEAN PERRIN   (France)

^v TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^w CENTRE FRANÇOIS BACLESSE   (France)

^x GLASGOW ROYAL INFIRMARY   (United Kingdom)

^y ACADEMIC MEDICAL CENTER   (Netherlands)

^z SmithKline Beecham Pharmaceuticals ^*  (France)

^aa GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Dexamethasone; Emesis; Fractionated chemotherapy; Granisetron; Metoclopramide

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; IFOSFAMIDE; METOCLOPRAMIDE;

ADULT; AGITATION; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; EXTRAPYRAMIDAL SYNDROME; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; COMPARATIVE STUDY; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; GRANISETRON; HUMAN; IFOSFAMIDE; INDAZOLES; MALE; METOCLOPRAMIDE; MIDDLE AGE; VOMITING;

EID: 0027176140     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/BF01686466     Document Type: Article

References (17)

1. Neuropharmacology of emesis induced by anti-cancer therapy
2. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis
3. Paraneoplastic syndromes
4. Efficacy and safety of granisetron compared with high dose metoclopramide plus dexamethasone in patients receiving high dose cisplatin in a single-blind study
5. On the receiving end-patient perception of the side effects of cancer chemotherapy
6. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
7. New approaches to the control of emesis; serotonin antagonists as antiemetics
8. Serotonin antagonists: a new class of antiemetic agents
9. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective randomized, double-blind trial
10. Evidence that 5-hydroxytryptamine-3 receptors mediate cytotoxic drug and radiation-evoked emesis
11. Infections in the cancer patient
12. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy
13. A comparison of two dose levels of granisetron in patients receiving high dose cisplatin
14. Optimum management of nausea and vomiting in cancer chemotherapy
15. New antiemetic drugs
16. The clinical pharmacology of granisetron (BRL.43694), a novel specific 5-HT3 antagonist
17. The concept of selectivity in 5-HT receptor research